<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33577738</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-5116</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>59</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical biology</Title>
          <ISOAbbreviation>Pharm Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evodiamine protects against airway remodelling and inflammation in asthmatic rats by modulating the HMGB1/NF-κB/TLR-4 signalling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>192</StartPage>
          <EndPage>199</EndPage>
          <MedlinePgn>192-199</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13880209.2020.1871374</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Evodiamine, which is isolated from <i>Evodia rutaecarpa</i> (Rutaceae), possess strong anti-inflammatory, immunomodulatory, and antibacterial properties.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The protective effects of evodiamine in asthma were evaluated.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Thirty-two Sprague-Dawley (SD) rats were used, asthma was induced by injecting intraperitoneally with a mixture of Al(OH)<sub>3</sub> (100 mg) and ovalbumin (OA; 1 mg/kg), further exposing them to a 2% OA aerosol for 1 week. All animals were divided into four groups: control, asthma, and evodiamine 40 and 80 mg/kg p.o. treated group. Serum levels of inflammatory cytokines, interferon gamma (IFN-γ), and immunoglobulin E (IgE) and infiltrations of inflammatory cells in the bronchoalveolar lavage fluid (BALF) of the animals were determined. The thickness of the smooth muscle layer and airway wall in the intact small bronchioles of asthmatic rats was examined as well.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Cytokine levels in the serum and BALF were lower in the evodiamine-treated group than in the asthma group. Evodiamine treatment reduced IgE and IFN-γ levels as well as the inflammatory cell infiltrate in the lung tissue of asthmatic rats. The thickness of the smooth muscle layer and airway wall of intact small bronchioles was less in the evodiamine-treated group than in the asthma group. Lower levels of TLR-4, MyD88, NF-κB, and HMGB1 mRNA in lung tissue were measured in the evodiamine-treated group than in the asthma group.</AbstractText>
          <AbstractText Label="DISCUSSION AND CONCLUSION" NlmCategory="CONCLUSIONS">The effect of evodiamine treatment protects the asthma, as evodiamine reduces airway inflammation and remodelling in the lung tissue by downregulating the HMGB1/NF-κB/TLR-4 pathway in asthma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qiong</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Laboratory, Wuxi People's Hospital Affiliated to Nanjing Medical University, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Yubao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Laboratory, Wuxi People's Hospital Affiliated to Nanjing Medical University, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Xufeng</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chinese Traditional Medicine, Wuxi People's Hospital Affiliated to Nanjing Medical University, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Junfang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopaedics, Wuxi People's Hospital Affiliated to Nanjing Medical University, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pharm Biol</MedlineTA>
        <NlmUniqueID>9812552</NlmUniqueID>
        <ISSNLinking>1388-0209</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C104200">Hbp1 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495347">Tlr4 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>C01825BVNL</RegistryNumber>
          <NameOfSubstance UI="C049639">evodiamine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D056151" MajorTopicYN="N">Airway Remodeling</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001249" MajorTopicYN="N">Asthma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001992" MajorTopicYN="N">Bronchoalveolar Lavage Fluid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032086" MajorTopicYN="N">Evodia</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Asthma</Keyword>
        <Keyword MajorTopicYN="N">bronchioles</Keyword>
        <Keyword MajorTopicYN="N">cytokine</Keyword>
        <Keyword MajorTopicYN="N">lung</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no declarations of interest. The authors alone are responsible for the content and writing of the paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>20</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33577738</ArticleId>
        <ArticleId IdType="pmc">PMC7889089</ArticleId>
        <ArticleId IdType="doi">10.1080/13880209.2020.1871374</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Azam S, Jakaria M, Kim IS, Kim J, Haque ME, Choi DK.. 
2019. Regulation of Toll-Like Receptor (TLR) Signaling pathway by polyphenols in the treatment of age-linked neurodegenerative diseases: Focus on TLR4 signaling. Front Immunol. 10:1000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6522942</ArticleId>
            <ArticleId IdType="pubmed">31134076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baek SE, Park SY, Bae SS, Kim K, Lee WS, Kim CD.. 
2018. BLTR1 in monocytes emerges as a therapeutic target for vascular inflammation with a subsequent intimal hyperplasia in a murine wire-injured femoral artery. Front Immunol. 9:1938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6121004</ArticleId>
            <ArticleId IdType="pubmed">30210495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergeron C, Tulic MK, Hamid Q.. 
2010. Airway remodelling in asthma: from benchside to clinical practice. Can Respir J. 17(4):e85–e93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2933777</ArticleId>
            <ArticleId IdType="pubmed">20808979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME.. 
2003. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. Embo J. 22(20):5551–5560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC213771</ArticleId>
            <ArticleId IdType="pubmed">14532127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christian F, Smith EL, Carmody RJ.. 
2016. The regulation of NF-κB subunits by phosphorylation. Cells. 5(1):12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4810097</ArticleId>
            <ArticleId IdType="pubmed">26999213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dharmage SC, Perret JL, Custovic A.. 
2019. Epidemiology of asthma in children and adults. Front Pediatr. 7:246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6591438</ArticleId>
            <ArticleId IdType="pubmed">31275909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durrant DM, Metzger DW.. 
2010. Emerging roles of T helper subsets in the pathogenesis of asthma. Immunol Invest. 39(4-5):526–549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3787690</ArticleId>
            <ArticleId IdType="pubmed">20450290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fehrenbach H, Wagner C, Wegmann M.. 
2017. Airway remodeling in asthma: what really matters. Cell Tissue Res. 367(3):551–569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5320023</ArticleId>
            <ArticleId IdType="pubmed">28190087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galli SJ, Tsai M.. 
2012. IgE and mast cells in allergic disease. Nat Med. 18(5):693–704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3597223</ArticleId>
            <ArticleId IdType="pubmed">22561833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou C, Kong J, Liang Y, Huang H, Wen H, Zheng X, Wu L, Chen Y.. 
2015. HMGB1 contributes to allergen-induced airway remodeling in a murine model of chronic asthma by modulating airway inflammation and activating lung fibroblasts. Cell Mol Immunol. 12(4):409–423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4496537</ArticleId>
            <ArticleId IdType="pubmed">25152078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang J, Hu C.. 
2009. Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules. 14(5):1852–1859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6254303</ArticleId>
            <ArticleId IdType="pubmed">19471205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li CG, Zeng QZ, Chen MY, Xu LH, Zhang CC, Mai FY, Zeng CY, He XH, Ouyang DY.. 
2019. Evodiamine augments NLRP3 inflammasome activation and anti-bacterial responses through inducing α-tubulin acetylation. Front Pharmacol. 10:290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6443907</ArticleId>
            <ArticleId IdType="pubmed">30971927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao JF, Chiou WF, Shen YC, Wang GJ, Chen CF.. 
2011. Anti-inflammatory and anti-infectious effects of Evodia rutaecarpa (Wuzhuyu) and its major bioactive components . Chin Med. 6(1):6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3046897</ArticleId>
            <ArticleId IdType="pubmed">21320305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Zhang L, Joo D, Sun SC.. 
2017. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2:17023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5661633</ArticleId>
            <ArticleId IdType="pubmed">29158945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moldoveanu B, Otmishi P, Jani P, Walker J, Sarmiento X, Guardiola J, Saad M, Yu J.. 
2009. Inflammatory mechanisms in the lung. J Inflamm Res. 2:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3218724</ArticleId>
            <ArticleId IdType="pubmed">22096348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. 
2007. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda (MD): National Heart, Lung, and Blood Institute (US); Section 2, Definition, Pathophysiology and Pathogenesis of Asthma, and Natural History of Asthma.</Citation>
        </Reference>
        <Reference>
          <Citation>Qu L, Chen C, Chen Y, Li Y, Tang F, Huang H, He W, Zhang R, Shen L.. 
2019. High-mobility group box 1 (HMGB1) and autophagy in acute lung injury (ALI): A review. Med Sci Monit. 25:1828–1837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6423734</ArticleId>
            <ArticleId IdType="pubmed">30853709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen P, Zhang Z, Zhu K, Cao H, Liu J, Lu X, Li Y, Jing Y, Yuan X, Fu Y, et al. . 
2019. Evodiamine prevents dextran sulfate sodium-induced murine experimental colitis via the regulation of NF-κB and NLRP3 inflammasome. Biomed Pharmacother. 110:786–795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30554117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sprague AH, Khalil RA.. 
2009. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 78(6):539–552.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2730638</ArticleId>
            <ArticleId IdType="pubmed">19413999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Li R, Peng Z, Hu B, Rao X, Li J.. 
2020. HMGB1 participates in LPS-induced acute lung injury by activating the AIM2 inflammasome in macrophages and inducing polarization of M1 macrophages via TLR2, TLR4, and RAGE/NF-κB signaling pathways. Int J Mol Med. 45(1):61–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6889921</ArticleId>
            <ArticleId IdType="pubmed">31746367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamauchi K, Ogasawara M.. 
2019. The role of histamine in the pathophysiology of asthma and the clinical efficacy of antihistamines in asthma therapy. IJMS. 20(7):1733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6480561</ArticleId>
            <ArticleId IdType="pubmed">30965592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H, Jin H, Gong W, Wang Z, Liang H.. 
2013. Pharmacological actions of multi-target-directed evodiamine. Molecules. 18(2):1826–1843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6270287</ArticleId>
            <ArticleId IdType="pubmed">23434865</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
